Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome
Aditi Sinha, Arvind Bagga(All India Institute of Medical Sciences), Abhijeet Saha, Pankaj Hari(Indian Council of Medical Research), Amarjeet Mehta(SMS Medical College), Manish Kumar(Sterling Hospitals), Mani Kalaivani(All India Institute of Medical Sciences), Kamran Afzal(Jawaharlal Nehru Medical College Hospital), Sonia Sharma(All India Institute of Medical Sciences)
Cited by 126
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203